Neurodegenerative Diseases and Medical Cannabis in Texas

“Incurable neurodegenerative disease” is a legal category in the Texas Compassionate Use Program, not a claim that cannabis treats every disease in the category. The state rule names particular diagnoses, while cannabinoid research is strongest for a few symptom and formulation combinations and weak or absent for many others. The practical task is to separate eligibility from efficacy.

What Texas Means by an Incurable Neurodegenerative Disease

Texas DPS lists an incurable neurodegenerative disease as a qualifying category.¹ DSHS explains that the state adopted a rule identifying the diseases included in that category, and the current rule defines an incurable neurodegenerative disease as a condition, injury, or illness in which nerve cells in the brain or peripheral nervous system lose function over time and for which there is no known cure.²³

The rule is more specific than the category label. A chart that says only “dementia,” “neuropathy,” or “movement disorder” may not be enough to establish eligibility. The documented diagnosis should be compared with the current rule, especially when a disease has several subtypes or a similar name.

Which Diagnoses the Texas Rule Names

For adult-onset disease, the rule includes named motor-neuron diseases, muscular dystrophies, ataxias, hereditary neuropathies, progressive dystonias and choreas, dementias, prion diseases, tauopathies, synucleinopathies, and TDP-43 proteinopathies. Examples include spinal-bulbar muscular atrophy, spinal muscular atrophy, Friedreich’s ataxia, vascular dementia, Charcot-Marie-Tooth and related hereditary neuropathies, Huntington’s disease, Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, multiple system atrophy, frontotemporal lobar degeneration, primary lateral sclerosis, and progressive muscular atrophy.³

The pediatric-onset portion is also extensive. It includes named mitochondrial conditions, organic acidemias, amino acid metabolism defects, urea-cycle disorders, lysosomal storage disorders, peroxisomal disorders, leukodystrophies, fatty-acid oxidation disorders, metal-metabolism disorders, neurodegeneration with brain iron accumulation, and purine or pyrimidine defects. Some categories contain precise subtypes rather than every disorder in the family.

This guide does not replace the official list. Patients with a rare diagnosis should bring the exact neurologist or genetics report, including subtype and gene information when relevant, and ask the registered physician to verify it against the current version of 25 TAC Section 1.61. DSHS also maintains a process through which physicians may request that a medical condition be added.²

Eligibility Does Not Prove Clinical Benefit

Texas eligibility answers whether a physician may consider a prescription. It does not show that cannabis cures, reverses, or slows the underlying neurodegenerative disease. Laboratory findings about inflammation, oxidative stress, protein aggregation, or the endocannabinoid system are not the same as evidence that a product changes the course of disease in people.

The National Academies found substantial evidence for oral cannabinoids improving patient-reported spasticity symptoms in multiple sclerosis, but only limited evidence for improving symptoms associated with dementia and insufficient evidence for several other neurologic outcomes.⁴ A 2025 systematic review of cannabinoid clinical trials across neurologic conditions similarly found that evidence depends on the condition, product, dose, trial design, and outcome measured.⁵

That is why condition-specific guidance matters. Evidence for a studied oral cannabinoid formulation in multiple-sclerosis spasticity cannot be transferred automatically to Parkinson’s tremor, Huntington’s chorea, Alzheimer’s cognition, hereditary neuropathy, or a pediatric metabolic disorder. Even when a symptom signal exists, it may not apply to the formulation available through a Texas dispensing organization.

Risks Can Be Different in Neurologic Disease

THC can affect attention, short-term memory, coordination, reaction time, perception, mood, and judgment. Dizziness, sedation, anxiety, hallucinations, or a fall can be especially consequential for someone who already has cognitive impairment, gait instability, low blood pressure, swallowing difficulty, respiratory weakness, or behavioral symptoms.

CBD is not risk-free. FDA guidance warns that CBD can cause liver injury, drowsiness, gastrointestinal effects, mood changes, and clinically important drug interactions.⁶ The concern is practical because people with neurodegenerative disease often take several medicines, including antiseizure drugs, blood thinners, antidepressants, antipsychotics, sleep medicines, muscle relaxants, or medicines for blood pressure and movement symptoms.

• Review every prescription, nonprescription medicine, supplement, and cannabinoid product with the neurologic care team.
• Ask whether the proposed product could worsen confusion, hallucinations, impulsivity, orthostatic hypotension, balance, or swallowing.
• Confirm the exact THC and CBD amount per dose, route, timing, and maximum daily use.
• Do not replace disease-modifying, seizure, movement, psychiatric, or supportive treatment without the prescribing clinician.
• Plan for caregiver observation when memory, communication, or decision-making is impaired.
• Do not drive or operate machinery while impaired. FDA warns that cannabis and CBD can make driving dangerous.⁷

Questions to Bring to the Physician

• Does the exact diagnosis and subtype appear in the current Texas rule?
• What symptom are we trying to improve, and what would count as a meaningful change?
• Does clinical evidence support this specific cannabinoid, route, and symptom?
• Could the product worsen cognition, balance, behavior, blood pressure, breathing, or swallowing?
• Which medicines create interaction or added-sedation concerns?
• Who will monitor benefit, adverse effects, liver tests, and dose changes?
• When should the trial stop because benefit is absent or harms are emerging?

How the Texas Process Works

Start with the official CURT participating physician search.⁸ Bring proof of Texas residency, the exact diagnostic records, a current medication and supplement list, recent specialist notes, and the symptom goals being considered. A registered physician reviews the qualifying diagnosis and decides whether the potential benefit is reasonable in light of the risk.

If approved, the physician enters the patient and prescription in CURT. The patient or legal guardian then works with a licensed Texas dispensing organization. For more detail, review the complete Texas qualifying-conditions guide, the Alzheimer’s and dementia guide, the ALS guide, the multiple-sclerosis and spasticity guide, and the medication-interaction checklist.